Achieve Life Sciences, Inc. (ACHV) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Achieve Life Sciences, Inc. is a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of cytisinicline, a plant-based alkaloid for smoking and e-cigarette cessation. The company has no approved products and has not generated product revenue to date. In June 2025, the company submitted a New Drug Application (NDA) to the FDA for cytisinicline for smoking cessation.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(25.5) million | $(15.0) million |
| Operating Expenses | $25.5 million | $14.4 million |
| Cash & Cash Equivalents | $51.9 million | $12.8 million (Dec 31, 2024) |
| Marketable Securities | $3.5 million | $21.6 million (Dec 31, 2024) |
| Total Liquidity (Cash + Securities) | $55.4 million | $34.4 million (Dec 31, 2024) |
| Convertible Debt (Principal) | $10.0 million | $10.0 million |
| Accumulated Deficit | $(231.1) million | $(205.6) million (Dec 31, 2024) |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2025, increased to $25.5 million from $15.0 million in the prior year period. This was driven by higher Research and Development (R&D) expenses ($13.8 million vs. $7.9 million) due to the full enrollment of the ORCA-OL open-label safety trial, and increased General and Administrative (G&A) expenses ($11.7 million vs. $6.5 million) due to commercial launch preparation and higher stock-based compensation.
- Capital Raise: In June 2025, the company completed a public offering of 15 million shares and accompanying warrants, raising approximately $41.2 million in net proceeds. This significantly improved liquidity compared to the prior period.
- Regulatory Milestone: The company submitted its NDA to the FDA in June 2025, a critical step not present in the prior comparable period.
- Debt Structure: The company refinanced its debt in July 2024 with a new $10 million convertible term loan from SVB/FCB, which bears interest-only payments until December 2025 (potentially extendable to June 2026).
Outlook, Risks, and Contingencies
- Commercialization Timeline: If approved, the company plans to commence commercial sales in the U.S. in the second half of 2026. They are preparing a commercial infrastructure utilizing AI tools and a partnership with Omnicom.
- Supply Chain Dispute: The company has concerns regarding its primary supplier, Sopharma, passing an FDA pre-approval inspection. Achieve included third-party manufacturers in its NDA submission. Sopharma has alleged this is a breach of contract, a dispute the company is actively managing.
- Liquidity Runway: Management believes current cash and marketable securities ($55.4 million) are sufficient to fund operations into the second half of 2026. However, the company remains dependent on raising additional capital for future development and commercialization.
- Regulatory Risks: Approval is not guaranteed. The FDA may require additional studies. The company also faces risks related to the Breakthrough Therapy designation for vaping cessation, which does not guarantee faster approval.
- Intellectual Property: Cytisinicline is a naturally occurring substance and not eligible for composition of matter patents in the U.S. The company relies on formulation patents and regulatory exclusivity.
Investor Verification Checklist
- NDA Review Status: Verify the current status of the FDA review of the June 2025 NDA submission and any potential requests for additional data.
- Supplier Resolution: Monitor the resolution of the dispute with Sopharma regarding third-party manufacturing and FDA inspection readiness.
- Cash Burn Rate: Assess the sustainability of the current cash position ($55.4 million) against the projected burn rate to confirm the runway into late 2026.
- Debt Conversion Terms: Review the conversion triggers for the $10 million SVB convertible debt (conversion price $7.00; mandatory conversion if stock price exceeds $24.00 for 30 days).
- Commercial Readiness: Evaluate the progress of the commercial launch team and the Omnicom partnership ahead of a potential 2026 launch.